Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544348 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 295
- Enrollment target
NCT01544348 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 295 participants.
The verdict
NCT01544348, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 295 participants
- Enrollment target
Study Summary
Phase 1 study to evaluate the safety of MEDI4212.
Interventions
- OTHER Placebo
- BIOLOGICAL Omalizumab
- BIOLOGICAL MEDI4212 5 mg Subcutaneous
- BIOLOGICAL MEDI4212 15 mg Subcutaneous
- BIOLOGICAL MEDI4212 60 mg Subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01544348
The ClinicalTrials.gov registry entry for NCT01544348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01544348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01544348 about?
NCT01544348 is a clinical study titled "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL". Phase 1 study to evaluate the safety of MEDI4212.
What is the current status of trial NCT01544348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 295 participants. The study started on 2012-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01544348?
The interventions under investigation include: Placebo (OTHER), Omalizumab (BIOLOGICAL), MEDI4212 5 mg Subcutaneous (BIOLOGICAL), MEDI4212 15 mg Subcutaneous (BIOLOGICAL), MEDI4212 60 mg Subcutaneous (BIOLOGICAL).
Who is sponsoring clinical trial NCT01544348?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.